Clin Osteol 2003; 8(3): 75-81

Quality of bone: what effects of treatment can be monitored and what does it require?Articles

J. Štěpán

For monitoring skeletal effects of the antiresorption treatments it is advantageous to employ techniques aimed to a quantitative assessment of specific aspects of quality of bone that respond most significantly to the treatment and best reflect the mechanisms of action of the drug. Some treatment mo­ des, such as aminobisphosphonates, are best assessed using the bone mineral density measurement (BMD), while evaluation of bone resorption using biochemical markers is most suitable to judge efficacy of treatment with estradiol, raloxifene, and calcitonin. Monitoring enables to identify patients not responding to the treatment or not compliant. The information provided by BMD may be further elaborated using the biochemical markers. The Least Significant Change enables an appropriate clinical interpretation of the measurements. The clinical utilization of the biochemical markers re­ quires a further standardisation and comprehensive validation.

Keywords: bisphosphonates, bone mineral, bone markers, monitoring, quality of bone.

Published: December 11, 2003  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Štěpán J. Quality of bone: what effects of treatment can be monitored and what does it require? Osteologický bulletin. 2003;8(3):75-81.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Lufkin EG, Whitaker MD, Nickelsen T, et al. Treatment of established postmeno­ pausal oste 13:1747-54.
    2. Maricic M, Adachi JD, Sarkar S, et al. Early effects of raloxifene on clinical v tebral fractures at 12 months in postmenopausal women with osteoporosis. Arch Intern Med 2002;162:1140-3. Go to original source...
    3. Pols HA, Felsenberg D, Hanley DA, et al. Multinational, placebo-controlled, ran­ domized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results ofthe FOSIT study. Foxamax International Trial Study Group. Osteoporos Int 1999;9:461-8. Go to original source...
    4. Reginster J, Minne HW, Sorensen OH, et al. Randomized trial of the effects o sedronate on vertebral fractures in women with established postmenopausal oste­ oporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Os­ teoporos Int 2000;11:83-91. Go to original source...
    5. Cranney A, Tugwell P, Adachi J, et al. Meta-analysis of rised ment of postmenopausal osteoporosis. Endocr Rev 2002;23:517-523. Go to original source...
    6. Cranney A, Wells G, Willan A, et al. Meta-analysis of ment of postmenopausal women. Endocr Rev 2002;23:508-516. Go to original source...
    7. Cranney A, Tugwell P, Zytaruk N, et al. Meta-analysis of raloxifene fo vention and treatment of postmenopausal osteoporosis. Endocr Rev 2002;23: 524-528. Go to original source...
    8. Wells G, Tugwell P, Shea B, et al. Meta-analysis of the efficacy of hormone placement therapy in treating and preventing osteoporosis in postmenopausal wo­ men. Endocr Rev 2002;23:529-539. Go to original source...
    9. Cranney A, Tugwell P, Zytaruk N, et al. Meta-analysis of calc ment of postmenopausal osteoporosis. Endocr Rev 2002;23:540-551. Go to original source...
    10. van Beek E, Pieterman E, Cohen L, et al. Farnesyl pyrophosphate synthase molecular target of nitrogen-containing bisphosphonates. Biochem Biophys Res Commun 1999;264:108-11. Go to original source...
    11. Reszka AA, Halasy Nagy JM, Masarachia PJ, et al. Bisphosphonates act dire on the osteoclast to induce caspase cleavage of mst1 kinase during apoptosis. A link between inhibition of the mevalonate pathway and regulation of an apo­ ptosis-promoting kinase. J Biol Chem 1999;274:34967-73. Go to original source...
    12. Bergstrom JD, Bostedor RG, Masarachia PJ, et al. Alendronate is a specific nomolar inhibitor of farnesyl diphosphate synthase. Arch Biochem Biophys 2000; 373:231-41. Go to original source...
    13. Benford HL, Frith JC, Auriola S, et al. Farnesol and geranylgeraniol prevent a vation of caspases by aminobisphosphonates: biochemical evidence for two di­ stinct pharmacological classes of bisphosphonate drugs. Mol Pharmacol 1999;56: 131-40. Go to original source...
    14. Colucci S, Minielli V, Zambonin G, et al. Alendronate reduces adhesion ofhuman osteoclast-like cells to bone and bone protein-coated surfaces. Calcif Tissue Int 1998;63:230-5. Go to original source...
    15. Benford HL, McGowan NW, Helfrich MH, et al. Visualization of bisphosphona­ te-induced caspase-3 activity in apoptotic osteoclasts in vitro. Bone 2001;28: 465-73. Go to original source...
    16. Still K, Phipps RJ, Scutt A. Effects of risedronate, alendronate, and etidronate the viability and activity of rat bone marrow stromal cells in vitro. Calcif Tissue Int 2003;72:145-150. Go to original source...
    17. Eriksen EF, Melsen F, Sod E, et al. Effect of long-term risedronate on bone qua­ lity and bone turnover in women with postmenopausal osteoporosis. Bone 2002; 31:620-625. Go to original source...
    18. Currey JD. Changes in the impact energy absorption of bone with age. J Biomech 1979;12:459-69. Go to original source...
    19. Manolagas SC. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev 2000; 21:115-37. Go to original source...
    20. Boivin GY, Chavassieux PM, Santora AC, et al. Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteo­ porotic women. Bone 2000;27:687-94. Go to original source...
    21. Meunier PJ, Boivin G. Bone mineral density reflects bone mass but also the de­ gree of mineralization of bone: therapeutic implications. Bone 1997;21:373-7. Go to original source...
    22. Boivin G, Meunier PJ. Effects of bisphosphonates on matrix mineralization. J Musculoskel Neuron Interact 2002;2:538-543.
    23. Mashiba T, Turner CH, Hirano T, et al. Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone 2001;28:524-31. Go to original source...
    24. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alend­ ronate on risk of fracture in women with existing vertebral fractures. Fracture In­ tervention Trial Research Group. Lancet 1996;348(9041):1535-41. Go to original source...
    25. Liberman UA, Weiss SR, Broll J, et al. Effect of oral alendronate on bone mine­ ral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 1995; 333:1437-43. Go to original source...
    26. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998;280:2077-82. Go to original source...
    27. Tonino RP, Meunier PJ, Emkey R, et al. Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treat­ ment Study Group. J Clin Endocrinol Metab 2000;85:3109-15. Go to original source...
    28. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1 on fractures and bone mineral density in postmenopausal women with osteoporo­ sis. N Engl J Med 2001;344:1434-H. Go to original source...
    29. Khastgir G, Studd J, Holland N, et al. Anabolic effect of estrogen rep bone in postmenopausal women with osteoporosis: histomorphometric evidence in a longitudinal study. J Clin Endocrinol Metab 2001;86:289-95. Go to original source...
    30. Writing Group for the Women's Health Initiative I. Risks and benefits of e plus progestin in healthy postmenopausal women: principal results From the Wo­ men's Health Initiative randomized controlled trial. JAMA 2002;288:321-33. Go to original source...
    31. Taranta A, Brama M, Teti A, et al. The selective estrogen receptor modula loxifene regulates osteoclast and osteoblast activity in vitro. Bone 2002;30: 368-76. Go to original source...
    32. Delmas PD, Ensrud KE, Adachi JD, et al. Efficacy of raloxifene on vertebral ture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab 2002;87:3609-17. Go to original source...
    33. Meunier PJ, Sebert JL, Reginster JY, et al. Fluoride salts are no better at pr ting new vertebral fractures than calcium-vitamin D in postmenopausal osteopo­ rosis: the FAVOStudy. Osteoporos Int 1998;8:4-12. Go to original source...
    34. Cauley JA, Norton L, Lippman ME, et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat 2001; 65:125-34. Go to original source...
    35. Silverman SL, Greenwald M, Klein RA, et al. Effect of bone density information on decisions about hormone replacement therapy: a randomized trial. Obstet Gy­ necol 1997;89:321-5. Go to original source...
    36. Blake GM, Fogelman I. The role of bone density measurements in the evaluation of new treatments for osteoporosis. Curr Pharm Des 2002;8:1885-1905. Go to original source...
    37. Compston JE. Do we need to monitor anti-osteoporosis treatment anyway? Calcif Tissue Int 2003;72:328.
    38. Cummings SR, Palermo L, Browner W, et al. Monitoring osteoporosis therapy with bone densitometry: misleading changes and regression to the mean. Fracture Intervention Trial Research Group. JAMA 2000;283:1318-21. Go to original source...
    39. Štěpán JJ, Zikan V. Calcitonin load test to assess the efficacy of salmon calc nin. Clin Chim Acta 2003;v tisku. Go to original source...
    40. Hochberg MC, Ross PD, Black D, et al. Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral frac­ tures in women with postmenopausal osteoporosis. Fracture Intervention Trial Re­ search Group. Arthritis Rheum 1999;42:1246-54. Go to original source...
    41. Courtney AC, Wachtel EF, Myers ER, et al. Effects of loading rate on streng the proximal femur [published erratum appears in Calcif Tissue Int 1994 Nov;55: 402]. Calcif Tissue Int 1994;55:53-8. Go to original source...
    42. Kanis JA, Johnell O, Oden A, et al. Ten year probabilities of osteoporotic frac res according to BMD and diagnostic thresholds. Osteoporos Int 2001;12:989-95. Go to original source...
    43. Kanis JA, Johnell O, Oden A, et al. Risk of hip fracture according to the World Health Organization criteria for osteopenia and osteoporosis. Bone 2000;27: 585-90. Go to original source...
    44. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. Geneva: World Health Organisati­ on; 1994.
    45. Kanis JA Assessing the risk of vertebral osteoporosis. Singapore Med J 2002;43: 100-5.
    46. Miller PD, Zapalowski C, Kulak CA, et al. Bone densitometry: the best way to tect osteoporosis and to monitor therapy. J Clin Endocrinol Metab 1999;84: 1867-71. Go to original source...
    47. Cummings SR, Bates D, Black DM. Clinical use of bone densitometry: scientific review. JAMA 2002;288:1889-97. Go to original source...
    48. Kanis JA, Gluer CC. An update on the diagnosis and assessment of osteoporosis with densitometry. Committee of Scientific Advisors, International Osteoporosis Foundation. Osteoporos Int 2000;11:192-202. Go to original source...
    49. Bonnick SL, Johnston CC, Jr., Kleerekoper M, et al. I bone density measurements. J Clin Densitom 2001;4:105-10. Go to original source...
    50. Cummings SR, Rirfitt AM. Bone density regression to the mean and the ind dual patient. J Clin Endocrinol Metab 2001;86:4001-2. Go to original source...
    51. Haddaway MJ, Davie MW, McCall IW. Bone mineral density in healthy normal women and reproducibility of measurements in spine and hip using dual-energy X-ray absorptiometry. Br J Radiol 1992;65(771):213-7. Go to original source...
    52. Sievanen H, Koskue V, Rauhio A, et al. Peripheral quantitative computed tomo­ graphy in human long bone Miner Res 1998;13:871-82. Go to original source...
    53. Heilmann P, Wuster C, Prolingheuer C, et al. Measurement of forearm bone mi­ neral density: com Int 1998;62:383-7.
    54. Michaeli DA, Mirshahi A, Singer J, et al. A new x-ray based osteoporosis sc ning tool provides accurate and precise assessment of phalanx bone mineral con­ tent. J Clin Densitom 1999;2:23-30. Go to original source...
    55. Sievanen H, Oja P, Vuori I. Precision of dual-energy x-ray absorptiometry in termining bone mineral density and content of various skeletal sites. J Nucl Med 1992;33:1137-42.
    56. Gluer CC. Quantitative ultrasound techniques for the assessment of osteop expert agreement on current status. The International Quantitative Ultrasound Consensus Group. J Bone Miner Res 1997;12:1280-8. Go to original source...
    57. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment tebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 1999;282:1344-52. Go to original source...
    58. Boivin G, Chavassieux P, Meunier P. Histomorphometry of bone. Effects of dif­ ferent 7:5-9.
    59. Roschger P, Rinnerthaler S, Yates J, et al. Alendronate increases degree and formity of mineralization in cancellous bone and decreases the porosity in corti­ cal bone of osteoporotic women. Bone 2001;29:185-91. Go to original source...
    60. Weichetova M, Štěpán JJ, Michalska D, et al. COLIA1 polymorphism contributes to bone mineral density to assess prevalent wrist fractures. Bone 2000;26:287-90. Go to original source...
    61. Garnero P, Cloos P, Sornay Rendu E, et al. Type I collagen racemization and i merization and the risk of fracture in postmenopausal women: The OFELY pro­ spective study. J Bone Miner Res 2002;17:826-833. Go to original source...
    62. Genant HK, Gordon C, Jiang Y, et al. Advanced imaging of the macrostructure and microstructure of bone. Horm Res 2000;54 (Suppl 1):24-30. Go to original source...
    63. Majumdar S. Magnetic resonance imaging of trabecular bone structure. Top Magn Reson Imaging 2002;13:323-34. Go to original source...
    64. Faulkner KG, Cummings SR, Nevitt MC, et al. Hip axis length and osteoporotic fractures. Study of Osteoporotic Fractures Research Group. J Bone Miner Res 1995;10:506-8. Go to original source...
    65. Garnero P, Sornay-Rendu E, Claustrat B, et al. Biochemical markers of bone nover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study. J Bone Miner Res 2000;15:1526-36. Go to original source...
    66. van den Bergh JP, van Lenthe GH, Hermus AR, et al. Speed of sound reflects Young's modulus as assessed by microstructural finite element analysis. Bone 2000;26:519-24. Go to original source...
    67. Njeh CF, Hans D, Li J, et al. Comparison of six calcaneal quantitative u devices: precision and hip fracture discrimination. Osteoporos Int 2000; 11: 1051-62. Go to original source...
    68. Garnero P. Markers of bone ros Int 2000;11(Suppl 6):55-65. Go to original source...
    69. Eastell R, Garnero P, Vrijens B, et al. Influence of patient compliance with dronate therapy on bone turnover marker and bone mineral density response: The IMPACT Study. Calcif Tissue Int 2003;72:408.
    70. Bjarnason NH, Sarkar S, Duong T, et al. Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of ral fene treatment in postmenopausal osteoporosis. Osteoporos Int 2001;12:922-30. Go to original source...
    71. Hannon R, Blumsohn A, Naylor K, et al. Response of biochemical markers of bo­ ne turnover to hormone replacement therapy: impact of biological variability. J Bone Miner Res 1998;13:1124-33. Go to original source...
    72. Delmas PD, Eastell R, Garnero P, et al. The use of biochemical markers of bone turnover in osteoporosis. Committee of Scientific Advisors of the International Osteoporosis Foundation. Osteoporos Int 2000;11:612-17. Go to original source...
    73. Chesnut CH, Silverman S, Andriano K, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med 2000;109:267-76. Go to original source...
    74. Seibel MJ, Lang M, Geilenkeuser WJ. Interlaboratory variation of biochemical markers of bone turnover. Clin Chem 2001;47:1443-50. Go to original source...

    Return to the content


    Clinical Osteology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.